Navigation Links
Genmab Announces 2007 First Half Year Results
Date:8/22/2007

Summary: Genmab Reports Results for the Six Month Period Ended June 30,

2007

COPENHAGEN, August 22 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today results for the six month period ended June 30, 2007. During this period, Genmab reported the following results:

Genmab's revenues were DKK 279.6 million (approx. USD 50.7 million) for the first half of 2007. In the same period of 2006, Genmab recognized DKK 74.3 million (approx. USD 13.5 million) in revenues.

An Operating Loss of DKK 118.9 million (approx. USD 21.6 million). This compares to an Operating Loss of DKK 187.5 million (approx. USD 34.0 million) reported for the corresponding period of 2006.

Net Financial Income totaled DKK 31.8 million (approx. USD 5.8 million), compared to Net Financial Expenses of DKK 2.3 million (approx. USD 0.4 million) in the first six months of 2006. Net Financial Income has benefited from the higher average cash position, whereas the negative net financial income reported for the first half of 2006 was impacted by increasing interest rates and weakening of the USD against the DKK.

A Net Loss of DKK 87.0 million (approx. USD 15.8 million) compared to a Net Loss of DKK 189.8 million (approx. USD 34.4 million) for the same period in 2006. The Net Loss per share was DKK 2.01 (approx. USD 0.36) for the first half of 2007 compared to DKK 4.96 (approx. USD 0.90) in the first half of 2006.

Genmab ended the six month period with a cash position of DKK 3.980 billion (approx. USD 722 million), which is a net increase of DKK 2.256 million (approx. USD 409.4 million) from the end of 2006.

Highlights

During the second quarter of 2007, Genmab achieved a number of business and scientific milestones, as follows:

On June 29, Genmab regained all rights to HuMax-CD4(R) (zanolimumab) from Merck Serono S.A. and announced final data from the HuMax-CD4 Phase II data in cutaneous T-cell lymphoma (C
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... , , Bacteria, gram negative , , ... href="http://www.biocompare.com/techart.asp?id=575">Actinobacillus , pleuropnomoniae , ... href="http://www.biocompare.com/techart.asp?id=576">Actinomyces , viscosus <A , ... <A , ...
... , , , Katherine A. ... PhD, University of Texas-Houston Medical Center, , , ... Kimberly Vollmer, Brinkmann™ Instruments Inc., BioSystems Application , ... , , , INTRODUCTION: , ...
... , , 1 , ... , Precautions and warnings , , , ... , 3.1, Materials supplied with the kits ... Materials required but not supplied , , , ...
Cached Biology Technology:Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 2Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 3Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 4Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 5Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 6Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 7Efficient Transfection of Neurospora Crassa 2Efficient Transfection of Neurospora Crassa 3Efficient Transfection of Neurospora Crassa 4Efficient Transfection of Neurospora Crassa 5TripleMaster PCR System 2TripleMaster PCR System 3TripleMaster PCR System 4TripleMaster PCR System 5TripleMaster PCR System 6TripleMaster PCR System 7TripleMaster PCR System 8TripleMaster PCR System 9TripleMaster PCR System 10TripleMaster PCR System 11TripleMaster PCR System 12TripleMaster PCR System 13TripleMaster PCR System 14TripleMaster PCR System 15TripleMaster PCR System 16TripleMaster PCR System 17TripleMaster PCR System 18TripleMaster PCR System 19TripleMaster PCR System 20
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics Agency is ... and prevent counterfeit microcircuits from entering into its supply ... in-house microcircuit anti-counterfeit initiative dubbed DNA marking. The capability ... their reliability throughout the supply chain. The new quality ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation is fundamentally ... evident than at international borders. Over the past decade, ... veteran travelers to self process through border control via ... increasing number of airports, seaports, and land borders across ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... that are linked with the onset of Barrett,s oesophagus (BE), ... have been identified for the first time. The discovery of ... develop screening tests for people at high risk of developing ... that there may be genetic causes for BE as well ...
... Sunday, September 9, 2012 A new paper published online ... the second most common type of lung cancer may one ... other lung cancer patients. Squamous cell lung cancer ... cancer, ranking second only to lung adenocarcinoma in the number ...
... 7, 2012 The University of Illinois at ... teams joining the NASA Astrobiology Institute (NAI) to study the ... approximately $8 million. Nigel Goldenfeld, Swanlund Professor of ... Institute for Genomic Biology (IGB), will serve as the principal ...
Cached Biology News:Researchers find first evidence for a genetic cause for Barrett's oesophagus 2Researchers find first evidence for a genetic cause for Barrett's oesophagus 3New potential targets discovered for treating squamous cell lung cancers 2New potential targets discovered for treating squamous cell lung cancers 3University of Illinois at Urbana-Champaign awarded 5-year grant from NASA 2University of Illinois at Urbana-Champaign awarded 5-year grant from NASA 3
... HORIBA Jobin Yvons Protein 295 ex ... a protein sample in only a few ... the amino acids tyrosine and tryptophan, the ... powerful NanoLED-17, a pulsed diode emitting 295 ...
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... Unique, compact measuring instrument for calibrating single-channel ... design and the robust carrying case, the ... in the laboratory and on-site at the ... to use because the individual channels are ...
Biology Products: